Identifying Risk Factors for Exacerbation and Symptom Worsening—A Retrospective Cohort Study of Patients with Myasthenia Gravis in the United States (P1-11.010)
To identify baseline (enrollment) risk-factors for ≥1 self-reported exacerbation(s) in the past 6-months at first follow-up, and for a myasthenia gravis (MG) activities-of-daily-living (MG-ADL) score ≥2 point increase between baseline and first follow-up.
Authors
- Minjee Park
- Aurélie Chekroun Martinot
- Alonso Gutiérrez‐Romero (ORCID: https://orcid.org/0000-0001-6881-4770)
- Zia Choudhry
- Pushpa Narayanaswami (ORCID: https://orcid.org/0000-0002-9412-7349)
- Nolan Campbell (ORCID: https://orcid.org/0000-0002-9266-2030)
- Richard M. Nowak (ORCID: https://orcid.org/0000-0002-7453-9426)
- Raghav Govindarajan (ORCID: https://orcid.org/0000-0003-0419-9072)
- Nizar Souayah (ORCID: https://orcid.org/0000-0003-3873-3448)
- Michael Kutch
Institutions
- Johnson & Johnson (United States) (US)
- Janssen (Belgium) (BE)
- Hadassah Medical Center (IL)
- St. Elizabeth Healthcare (US)
- Yale University (US)
- Janssen Scientific Affairs (United States)
- Cytel (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211361
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00